Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab
Editor's Note:This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for…